Press Release
11 November 2026 15:13:00 CET

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2027

In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica's three largest shareholders or owner groups in terms of voting rights as of September 30, 2026, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2027 Annual General Meeting.

The nomination committee for Nanologica AB's AGM 2027 thus consists of the following three members:

- Carl-Johan Spak (Flerie Invest AB)
- Jeremie Trochu (Ardena Sweden AB)
- Niklas Sjöblom (Konstakademiens stiftelser)

The nomination committee together represents 60.2 percent of the votes and shares in Nanologica AB as of September 30, 2026.

The nomination committee's task is to present proposals for the 2027 AGM regarding the election of the chairman of the meeting, the number of board members to be elected by the meeting, election of the chairman of the board and other members of the board, board fees and any remuneration for committee work, election of auditors (if applicable) and auditors' fees, as well as proposals for the principles that shall apply to the composition and work of the nomination committee for the next AGM (if applicable).

The 2027 AGM is planned to be held in Stockholm on May 20, 2027. Shareholders who wish to submit proposals to Nanologica's nomination committee may do so by e-mail to valberedning@nanologica.com no later than January 31, 2027. The nomination committee's proposals will be presented in the notice convening the AGM and on the company's website.

For further information, please contact
Johanna Westerberg
Director IR, Communications and Marketing
johanna.westerberg@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science group that offers advanced solutions for the development, manufacture and purification of pharmaceuticals. By combining expertise in materials science, nanotechnology and chemical process development with contract development and manufacturing services, Nanologica supports the value chain from early development to commercial production of pharmaceuticals. The Group has particular strength in complex molecules and peptide-based drugs. The Group has appx. 70 employees and is headquartered in Södertälje, Sweden. Nanologica's share (ticker: NICA) has been listed on Nasdaq Stockholm's main market since 2022. For more information, please visit www.nanologica.com.

Attachments

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2027